Avastin Approval History

Avastin (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody for the treatment of metastatic colorectal cancer, non-small cell lung cancer, HER2-negative breast cancer, glioblastoma, renal cell carcinoma, and cervical cancer.

FDA Approval History for Avastin

DateArticle
Aug 14, 2014Approval FDA Approves Avastin for Metastatic Cervical Cancer
Aug  3, 2009Approval FDA Approves Avastin for the Most Common Type of Kidney Cancer
May  6, 2009Approval FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Feb 25, 2008Approval FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Oct 11, 2006Approval FDA Approves Avastin in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Apr 12, 2006Avastin Filed in US for Treatment of Most Common Form of Lung Cancer
Feb 26, 2004Approval Avastin Approved for treatment for Metastatic Colorectal Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)